Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...

“We have already adopted the strategy of a checkpoint inhibitor [pembrolizumab] after chemoradiation for stage ... tertiary ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

This investigator-initiated, single-arm, open-label, phase 2 study evaluates the efficacy and safety of a triple combination regimen of pembrolizumab plus plinabulin/docetaxel. The study intends to ...

The trial will enrol patients with mCRC who are microsatellite stable (MSS), wild type (WT) RAS, WT BRAF, and human epidermal ...

A 2020 open-label, phase 2 study, for instance, found that pembrolizumab demonstrated activity in brain metastases in about 30% of patients (11 of 37) with untreated or previously treated stable brain ...

This open-label NIPPON, JCOG2007 study was conducted ... to receive four cycles of platinum-based chemotherapy plus pembrolizumab or two cycles of platinum-based chemotherapy plus nivolumab ...

Exelixis develops and commercializes new molecular entities to treat cancer. Its flagship product, cabozantinib, is marketed ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft ...